Clinical Investigation Evaluating the Safety and Feasibility of Adipearl
NCT06034522 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2025-09-23
Summary
Adipearl is an injectable filler intended to be injected subcutaneously in the face.
Conditions
- Mid-face Volume Deficiency
Interventions
- DEVICE
-
Adipearl
Injection of the investigational device in the face.
Sponsors & Collaborators
-
Volumina Medical S.A.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 22 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-11-25
- Primary Completion
- 2025-11-30
- Completion
- 2026-11-30
Countries
- Sweden
Study Locations
More Related Trials
-
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
NCT00304265 ·Status: COMPLETED ·Phase: PHASE4
-
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
NCT00319553 ·Status: COMPLETED ·Phase: PHASE4
-
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
NCT01346293 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults
NCT00928785 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China
NCT01933776 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants
NCT06344065 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents
NCT01689324 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Adacel® Booster Vaccination for CMI Assay Development
NCT04543669 ·Status: COMPLETED ·Phase: PHASE4
-
Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
NCT02382913 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Adacel® Vaccine Administered to Persons 10 Years of Age
NCT01311557 ·Status: COMPLETED ·Phase: PHASE4
-
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
NCT00325130 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)
NCT01294605 ·Status: COMPLETED ·Phase: PHASE4
-
10-year Follow-up After a Single Dose Acellular Pertussis Vaccination
NCT06803524 ·Status: RECRUITING ·Phase: PHASE4
-
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
NCT01629589 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
NCT00346073 ·Status: COMPLETED ·Phase: PHASE3
-
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
NCT00802867 ·Status: COMPLETED ·Phase: PHASE4
-
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
NCT00258882 ·Status: COMPLETED
-
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
NCT00347958 ·Status: COMPLETED ·Phase: PHASE4
-
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines
NCT00004800 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults
NCT01033877 ·Status: COMPLETED ·Phase: PHASE3
-
Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.
NCT01993173 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.
NCT00263679 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine
NCT01262924 ·Status: COMPLETED ·Phase: PHASE3
-
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
NCT00109330 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
NCT00467519 ·Status: COMPLETED ·Phase: PHASE3